Bremelanotide
Also known as: PT-141, Vyleesi
Research on bremelanotide (PT-141), a melanocortin receptor agonist peptide studied for hypoactive sexual desire disorder.
What does the research say about Bremelanotide?
Bremelanotide activates melanocortin pathways linked to sexual behavior and autonomic function. Literature includes phase 3 HSDD trials and mechanistic melanocortin pharmacology studies.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: Bremelanotide
11 indexed papers matched to curated MeSH concepts in the last 90 days.
(060) Comparison of Prescribing and Google Trends Between Bremelanotide (Vyleesi®) and Flibanserin (Addyi®) for Female Hypoactive Sexual Desire Disorder
Analysis compares prescribing patterns and online search trends for HSDD medications in women, suggesting gaps in patient education.
(025) Analysis of Off-Label Medication Prescriptions and Google Search Trends for Postmenopausal Female Hypoactive Sexual Desire Disorder
Analysis reveals common off-label prescriptions for HSDD treatments in postmenopausal women, suggesting awareness gaps.
Ionic Strength Impact on miR-141 Detection by bioFET
Investigation of ionic strength effects on miR-141 detection in a bioFET biosensor, highlighting optimal conditions for clinical applications.
(118) Desire Beyond Cisgender Monogamy: Inclusivity Gaps in the Evidence Base for FDA Approved Meds for HSDD
Narrative review identifies inclusivity gaps in HSDD medication trials, suggesting broader research for diverse populations.
Fe-PNC Nanoenzyme-Enhanced Closed Bipolar Sensing Platform for Sensitive ECL/Fluorescence Detection and Imaging of miRNA-141
A dual-mode biosensing platform detects microRNA-141 in human serum, suggesting enhanced bioimaging for early disease diagnosis.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Background: Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. Objective: To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions. Methods: A comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory documents, and preclinical studies were evaluated. A total of 20 primary sources were selected based on relevance, methodological quality, and contribution to understanding peptide mechanisms and clinical outcomes in aging populations. Results: Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide). FDA-approved agents demonstrated robust safety profiles from large-scale trials. Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. Significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. Conclusion: Therapeutic peptides offer mechanistically diverse approaches to multiple aging hallmarks. While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.
Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL
Functional characterization reveals that miR-141 and miR-200c affect overall survival in NSCLC patients with adenocarcinoma, indicating potential prognostic markers.
FDA‐Approved Drugs Containing D‐Amino Acids: A Historical and Developmental Perspective
Review traces historical development of d-amino acid drugs, highlighting mechanisms and innovations, suggesting significant therapeutic potential.
Direct Vapour–Solid Synthesis of Intermetallic Pt-Zn and Pt-Te Nanoparticles on Carbon: Enhanced Oxygen Reduction Through Te and Zn Incorporation
Randomized trial investigates enhanced catalytic activity in Pt-Zn and Pt-Te nanoparticles, suggesting effective material design for energy applications.
Quantification of “Mercy Sex” in Heterosexual Women
Randomized trials define and quantify mercy sex frequency in women with HSDD, suggesting important implications for therapy evaluation.
Researchers studying Bremelanotide
Researcher network data is loading or unavailable for this topic.
Follow Bremelanotide literature with AI-enriched clinical evidence on Synapse.
Search Bremelanotide on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers